BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
-4.98%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.46B
AUM Growth
+$3.46B
(-4.3%)
Cap. Flow
+$75.4M
Cap. Flow
% of AUM
2.18%
Top 10 Holdings %
Top 10 Hldgs %
66.74%
Holding
34
New
4
Increased
12
Reduced
7
Closed
2
Top Buys
| 1 |
TSRO
TESARO, Inc.
TSRO
|
$35.4M |
| 2 |
Esperion Therapeutics
ESPR
|
$30.2M |
| 3 |
Nektar Therapeutics
NKTR
|
$25.6M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$23.8M |
| 5 |
Exelixis
EXEL
|
$22.8M |
Top Sells
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$49.8M |
| 2 |
Agios Pharmaceuticals
AGIO
|
$28.4M |
| 3 |
Gilead Sciences
GILD
|
$21.3M |
| 4 |
Prothena Corp
PRTA
|
$14.7M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$12.7M |
Sector Composition
| 1 | Healthcare | 94.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $361M | 10.43% | 8,666,334 +150,000 | +2% | +$6.25M |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $326M | 9.41% | 3,317,753 -85,000 | -2% | -$8.35M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $264M | 7.62% | 3,324,298 | – | – |
|
4
Incyte
INCY
$16.5B
| $252M | 7.27% | 3,758,322 +60,000 | +2% | +$4.02M |
|
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $238M | 6.87% | 1,400,445 -75,000 | -5% | -$12.7M |
|
|
6
Agios Pharmaceuticals
AGIO
$2.19B
| $185M | 5.35% | 2,197,931 -337,322 | -13% | -$28.4M |
|
|
RDUS
7
DELISTED
Radius Health, Inc.
RDUS
| $183M | 5.28% | 6,200,913 +347,114 | +6% | +$10.2M |
|
|
8
Gilead Sciences
GILD
$140B
| $168M | 4.86% | 2,374,596 -300,000 | -11% | -$21.3M |
|
|
SAGE
9
DELISTED
Sage Therapeutics
SAGE
| $168M | 4.84% | 1,071,373 +68,934 | +7% | +$10.8M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $167M | 4.82% | 1,344,428 -50,000 | -4% | -$6.21M |
|
11
Halozyme
HALO
$8.56B
| $139M | 4.02% | 8,247,860 -272,277 | -3% | -$4.59M |
|
|
12
Esperion Therapeutics
ESPR
$448M
| $125M | 3.6% | 3,182,964 +770,000 | +32% | +$30.2M |
|
13
Alnylam Pharmaceuticals
ALNY
$58.5B
| $112M | 3.24% | 1,140,538 +129,200 | +13% | +$12.7M |
|
|
TSRO
14
DELISTED
TESARO, Inc.
TSRO
| $108M | 3.12% | 2,426,802 +797,059 | +49% | +$35.4M |
|
15
Regeneron Pharmaceuticals
REGN
$61.5B
| $93.1M | 2.69% | 270,000 -10,000 | -4% | -$3.45M |
|
|
MYOV
16
DELISTED
Myovant Sciences Ltd.
MYOV
| $80.2M | 2.32% | 3,507,882 | – | – |
|
|
AKCA
17
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $58.9M | 1.7% | 2,484,071 +94,500 | +4% | +$2.24M |
|
18
MacroGenics
MGNX
$112M
| $54.9M | 1.59% | 2,660,412 +60,000 | +2% | +$1.24M |
|
19
Voyager Therapeutics
VYGR
$186M
| $49.5M | 1.43% | 2,532,641 +540,000 | +27% | +$10.6M |
|
|
ICPT
20
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $45.8M | 1.32% | 545,719 | – | – |
|
21
Wave Life Sciences
WVE
$1.53B
| $43.5M | 1.26% | 1,137,885 +241,789 | +27% | +$9.25M |
|
|
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $38.9M | 1.12% | 2,200,000 | – | – |
|
23
argenx
ARGX
$43.6B
| $37.2M | 1.07% | 449,049 +52,230 | +13% | +$4.33M |
|
|
ALDR
24
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $35.8M | 1.03% | 2,266,008 | – | – |
|
|
25
Nektar Therapeutics
NKTR
$568M
| $25.6M | 0.74% | +525,000 | New | +$25.6M |
|